Bullous pemphigoid is the most common autoimmune blistering disease of the skin, and it overwhelmingly strikes older adults. The immune system mistakenly produces antibodies that attack proteins holding the outer layer of skin to the tissue beneath it, causing large, fluid-filled blisters and intense itching. While the condition can be alarming to look at and uncomfortable to live with, effective treatments exist, and most people achieve remission with proper care.
What Goes Wrong in the Skin
Your skin stays intact partly because of tiny anchor-like structures called hemidesmosomes that connect the outer layer (epidermis) to the layer underneath (dermis). Two proteins in these anchors, known as BP180 and BP230, are the targets in bullous pemphigoid. For reasons that are not fully understood, the immune system begins producing antibodies against one or both of these proteins.
Once those antibodies latch onto BP180 or BP230, they trigger part of the immune defense system called complement, which in turn summons waves of inflammatory cells, particularly eosinophils and neutrophils.1PubMed Central. The relevance of complement in pemphigoid diseases: A critical appraisal These cells release enzymes and other damaging molecules that break down the connections between the epidermis and dermis. Fluid fills the resulting gap, and a blister forms.2PubMed. The pathophysiology of bullous pemphigoid The blisters in bullous pemphigoid are “subepidermal,” meaning the split happens below the outer skin layer rather than within it, which is why they tend to be tense and firm rather than fragile and easily ruptured.
Who Gets Bullous Pemphigoid
Age is the single biggest risk factor. Bullous pemphigoid mainly appears in people over 70, and the rate climbs steeply after 80. In the general population, estimates of new cases per year range from roughly 2 to 23 per million people, but in those over 80 the figure jumps to roughly 190 to 312 per million.3PubMed Central. The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations A large English population study found the disease’s prevalence nearly doubled over two decades, reaching about 48 per 100,000 people overall and roughly 141 per 100,000 among those over 60.4British Journal of Dermatology. Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population‐based cohort study
Why does aging matter so much? Research supports the idea that changes in the skin barrier that come with aging increase susceptibility to the environmental and immunological triggers that set the disease in motion.5PubMed Central. Bullous pemphigoid: An immune disorder related to aging The incidence has also been rising in recent decades, which may partly reflect better detection. Newer blood tests for antibodies against BP180 and BP230 have made the disease easier to identify, likely catching cases that would have been missed in earlier eras.6PubMed Central. Diagnosis and clinical severity markers of bullous pemphigoid
Neurological Disease and Other Risk Factors
One of the more surprising findings in bullous pemphigoid research is its strong link to neurological conditions. A nationwide Finnish study found that various forms of dementia raised the risk of developing bullous pemphigoid substantially: unspecified dementia by about 3.8-fold, vascular dementia by about 3.6-fold, and Alzheimer’s disease by about 2.6-fold. Cerebrovascular events like intracerebral hemorrhage and cerebral infarction also carried elevated risk.7Scientific Reports. Psychiatric and neurological disorders are associated with bullous pemphigoid – a nationwide Finnish Care Register study Separate work has reported roughly a threefold increase in bullous pemphigoid risk among people with Parkinson’s disease, and about a twofold increase among those with stroke or epilepsy.8PubMed Central. Bullous pemphigoid and neurodegenerative diseases: a study in a setting of a Central European university dermatology department
The mechanism behind this connection is still debated. One leading hypothesis is that BP180 and BP230 are expressed in brain tissue as well as skin, so neurological damage may expose those proteins to the immune system in a way that eventually triggers an autoimmune response against the skin versions too. Whatever the underlying pathway, doctors evaluating someone with bullous pemphigoid will often screen for neurological conditions, and vice versa.
Drug Triggers
Certain medications can set off bullous pemphigoid, and a class of diabetes drugs called DPP-4 inhibitors (gliptins) has attracted particular attention. Multiple epidemiological studies have confirmed the association, especially for vildagliptin, though cases have also been reported with sitagliptin and linagliptin.9PubMed Central. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid 10National Journal of Physiology, Pharmacy and Pharmacology. Bullous pemphigoid associated with the use of DPP4 inhibitors: A case series The practical implication: if you develop new blistering while taking a gliptin, your dermatologist and endocrinologist should talk. Stopping or switching the drug sometimes leads to improvement, though immunosuppressive treatment is typically still needed.
COVID-19 vaccines have also been reported as a trigger in case series, with molecular mimicry between spike protein antibodies and certain tissue proteins proposed as a possible mechanism.11PubMed Central. Association between COVID-19 vaccination and bullous pemphigoid – a case series and literature review These reports remain uncommon relative to the hundreds of millions of doses administered, and the link is better described as a recognized but rare adverse event rather than a reason to avoid vaccination. Other medications occasionally implicated include certain diuretics, antibiotics, and checkpoint inhibitors used in cancer therapy, though the evidence for most individual drugs comes from scattered case reports rather than large studies.
What the Disease Looks and Feels Like
The hallmark of bullous pemphigoid is tense, dome-shaped blisters on skin that may look red and irritated, or sometimes completely normal. They most often appear on the trunk, arms, and legs. Unlike the fragile blisters of pemphigus (a different autoimmune blistering disease), these blisters are sturdy enough that they do not pop with gentle pressure.
Before blisters appear, many people go through a prodromal phase of intense itching and hive-like red patches that can last weeks or months. This pre-blistering phase is frequently misdiagnosed as eczema, hives, or a drug reaction, which delays proper treatment. The itch alone can be severe: in one prospective study, 85% of patients experienced daily itching with a mean intensity of about 5 out of 10, and the majority also reported tingling and burning sensations. Stress, fatigue, and dry skin tended to make the itch worse.12PubMed Central. Characteristics of Pruritus in Bullous Pemphigoid and Impact on Quality of Life: A Prospective Cohort Study This itch substantially impairs quality of life, affecting sleep, concentration, and social interaction, though treatment typically leads to meaningful improvements in itch scores and overall well-being.13JID Innovations. Exploring Pruritus in Bullous Pemphigoid: Analysis of QOL Metrics and Potential Biological Mechanisms
Although bullous pemphigoid is thought of as a skin disease, mucosal involvement is more common than many clinicians assume. One study of 327 patients found that about 17% had lesions on mucosal surfaces, most often the mouth (about 14%) and the larynx (about 5%), with genital involvement in about 3%.14JAMA Dermatology. Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid Mucosal involvement tends to track with more severe overall disease and, interestingly, appears to be independently associated with the absence of one of the two main antibodies (anti-BP230).15PubMed Central. Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody
How Bullous Pemphigoid Is Diagnosed
The gold standard test is direct immunofluorescence (DIF), in which a small skin biopsy is examined under a special microscope for a characteristic line of immune deposits (IgG and/or complement component C3) along the junction between the epidermis and dermis.16PubMed Central. Bullous pemphigoid diagnosis: the role of routine formalin-fixed paraffin-embedded skin tissue immunochemistry The biopsy should be taken from skin near a blister rather than from the blister itself, which produces the best diagnostic yield, with positive results in roughly 78–83% of cases from a single perilesional sample.17PubMed. Determination of the optimum site for diagnostic biopsy for direct immunofluorescence in bullous pemphigoid
A small percentage of patients will get a negative DIF result initially, sometimes because the biopsy was taken from the wrong spot or because antibody levels in the skin were too low to detect. If bullous pemphigoid is still suspected clinically, a repeat biopsy is warranted.18PubMed. Bullous Pemphigoid: A 10-Year Study of Discordant Results on Direct Immunofluorescence
Blood tests that measure circulating antibodies against BP180 and BP230 using ELISA have become an important complement to biopsy. The BP180 ELISA is particularly sensitive and specific, with one large study reporting sensitivity of about 95% and specificity of about 94%. The BP230 ELISA is less precise on its own but adds diagnostic confidence when positive alongside BP180.19PubMed. BP230- and BP180-specific auto-antibodies in bullous pemphigoid One wrinkle: about 7% of people without any known blistering disease tested positive for BP180 or BP230 antibodies in one study, so a positive ELISA alone does not seal the diagnosis without clinical correlation.20JAMA Dermatology. Anti–Bullous Pemphigoid 180 and 230 Antibodies in a Sample of Unaffected Subjects
First-Line Treatment With Corticosteroids
The backbone of bullous pemphigoid treatment is corticosteroids, and a landmark trial published in the New England Journal of Medicine reshaped how doctors approach them. In patients with extensive disease, applying a potent topical steroid (clobetasol propionate) to the whole body was not only as effective as taking oral prednisone but actually outperformed it: the one-year survival rate was 76% in the topical group versus 58% in the oral prednisone group, and severe complications were about half as common with topical treatment. Disease control at three weeks was achieved in 99% of the topical group versus 91% of the oral group.21PubMed. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid
A more recent study using U.S. insurance data reinforced the message: patients exposed to any dose of systemic (oral or injected) corticosteroids had a 43% higher all-time risk of death compared with those treated with topical clobetasol, along with higher rates of serious cardiac events and infections.22PubMed. Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids The catch: systemic steroids were slightly better at preventing relapse. In practice, many dermatologists now use topical clobetasol as the first choice whenever feasible, reserving oral steroids for cases where applying cream over the whole body is impractical, such as in frail patients without a caregiver who can help.
For patients with moderate disease, the original trial found no significant difference between topical and oral routes for survival, disease control, or complications, which gives doctors flexibility in choosing between the two based on patient preference and practical constraints.
Steroid-Sparing and Biologic Options
Because long-term corticosteroid use carries substantial side effects, especially in elderly patients, additional drugs are often introduced to keep the disease under control while tapering steroids down. Azathioprine and mycophenolate mofetil are the most commonly used steroid-sparing agents and appear to be roughly equally effective, though mycophenolate tends to cause fewer problems with bone marrow suppression and liver toxicity.23PubMed. Immunosuppressive therapy for autoimmune bullous diseases Doxycycline, an antibiotic with anti-inflammatory properties, has also been studied as a milder alternative, particularly for patients in whom immunosuppression poses too great a risk.
For cases that do not respond to conventional therapy, newer biologic medications are showing promise. A systematic review of published cases found that rituximab led to complete remission in about 71% of treated patients within roughly six months, while omalizumab achieved complete remission in about 68% and dupilumab in about 67%. Dupilumab stood out for having no reported adverse events in the pooled cases and the lowest recurrence rate at about 6%, though the total number of patients studied (36 for dupilumab) was small.24PubMed Central. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review None of these biologics is yet approved specifically for bullous pemphigoid, and researchers have called for larger controlled trials to determine which patients benefit most and how these agents compare head to head.25JAMA Dermatology. Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid
Relapse and Prognosis
Bullous pemphigoid tends to be a relapsing disease. After remission, published relapse rates range from about 28% to 53%, with most flares happening within the first six months of stopping treatment.26PubMed. Relapse of bullous pemphigoid: an update on this stubborn clinical problem In one multicenter prospective study, the mean time to relapse was about three months after therapy ended, and the strongest predictor of relapse was a high antibody titer at the start of treatment.27Archives of Dermatology. Risk Factors for Relapse in Patients With Bullous Pemphigoid in Clinical Remission: A Multicenter, Prospective, Cohort Study Another study identified extensive disease at diagnosis and co-existing dementia as independent risk factors for relapse within the first year.28JAMA Dermatology. Clinical and Immunologic Factors Associated With Bullous Pemphigoid Relapse During the First Year of Treatment
Mortality in bullous pemphigoid is higher than many people expect from a skin disease. The English population study found that the risk of death was nearly threefold higher than background in the two years after diagnosis and remained elevated even after that early window passed.4British Journal of Dermatology. Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population‐based cohort study Much of this excess mortality is attributable not to the blisters themselves but to the treatments (immunosuppression) and to the patient population being elderly with multiple other health problems. Infections are a particular concern: one large cohort study found that about 41% of patients with bullous pemphigoid developed a serious infection within two years of diagnosis, roughly double the rate in matched controls.29PubMed Central. Risk of Serious Infections in Patients with Bullous Pemphigoid: A Population-based Cohort Study
Day-to-Day Wound and Blister Care
Between doctor visits, practical wound care makes a real difference in comfort and complication rates. Small blisters are best left intact, as the blister roof acts as a natural bandage that protects the raw skin underneath from infection. Large blisters that are painful or at risk of rupturing on their own can be drained with a sterile needle while leaving the roof in place. The area should be gently cleaned with normal saline or a mild antiseptic, dried well, and then covered with a bland emollient and a non-adherent dressing.30Chronic Wound Care Management and Research. Management of chronic wounds in patients with pemphigus Adherent dressings can rip away healing skin, so anything that sticks is off the table. Weeping wounds need absorbent dressings; dry wounds benefit from something that keeps the area moist.
Keeping skin well-moisturized between flares helps reduce itching and may protect the skin barrier. Patients should be mindful of skin tears from friction or adhesive tape, since the compromised skin is more fragile than normal. Wearing soft, loose clothing and keeping nails short to avoid scratching damage are small measures that add up over time.
The Financial and Practical Burden
Bullous pemphigoid takes a financial toll that can catch patients off guard. A U.S. claims-data analysis found that people with the disease were hospitalized at more than twice the rate of matched controls (44% versus 17%), and their average monthly all-cause healthcare costs were more than double. Over a year, the cost gap widened further, driven largely by hospitalizations.31PubMed Central. Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims data For patients on Medicare or fixed incomes, the combination of frequent dermatology visits, lab work, biopsies, medications, and potential hospitalizations can become a significant stressor on top of the disease itself. Early and aggressive outpatient management, including the use of potent topical steroids to avoid systemic drug side effects, is one practical strategy that may reduce both health risks and downstream costs.